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Abstract
Background: Embelin is a potent dual inhibitor of 5-lipoxigenase (5-LOX) and microsomal prostaglandin E2 synthase
(mPGES)-1 that suppresses proliferation of human glioma cells and induces apoptosis by inhibiting XIAP and NF-κB
signaling pathway. Synthetic structural modification yielded the derivative 3-((decahydronaphthalen-6-yl)methyl)-2,5-
dihydroxycyclohexa-2,5-diene-1,4-dione (RF-Id), an embelin constrained analogue, with improved efficiency against 5-
LOX in human neutrophils and anti-inflammatory activity in vivo. Taking into account that lipoxygenase (LOX)
metabolites, from arachidonic acid and linoleic acid, have been implicated in tumor progression, here, we determined
whether RF-Id was able to hinder glioblastoma (GBM) cancer cell growth and the related mechanisms.
Methods: U87MG and LN229 cells were plated in 96-wells and treated with increasing concentrations of RF-Id. Cell
viability was evaluated by MTT assay. The effects of the compounds on cell cycle, apoptosis, oxidative stress and
autophagy were assessed by flow cytometry (FACS). The mode of action was confirmed by Taqman apoptosis array
and evaluating caspase cascade and NFκB pathway by western blotting technique.
Results: Here, we found that RF-Id induced a stronger inhibition of GBM cell growth than treatment with embelin.
Flow cytometry analysis showed that RF-Id induced about 30 % apoptosis and a slight increase of autophagy after
72 h on U87-MG cells. Moreover, the compound induced an increase in the percentage of cells in G2 and S phase that
was paralleled by an increase of p21 and p27 expression but no significant changes of the mitochondrial membrane
potential; array analysis showed a significant upregulation of CASP8 and a downregulation of IAP family and NFκB
genes in cells treated with RF-Id. RF-Id induced a significant cleavage of caspases 8, 9, 3 and 7, blocked c-IAP2/XIAP
interaction by inducing XIAP degradation and inhibited NFκB pathway.
Conclusions: RF-Id induced a caspase-dependent apoptosis in GBM cells by inhibiting IAP family proteins and NFκB
pathway and represents a promising lead compound for designing a new class of anti-cancer drugs with multiple targets.
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Background
Glioblastoma multiforme (GBM) is the most common and
deadliest of malignant primary brain tumors in adults.
Combination of radiotherapy and temozolomide (TMZ)
represents the gold-standard first-line treatment for GBM
[1, 2]. In recent phase II trials, also nitrosoureas such as
fotemustine (FTM) have shown mild activity for recurrent
GBM [3, 4]. The blood–brain barrier (BBB) is the most im-
portant limiting factor for the development of new drugs
and drug delivery for the central nervous system (CNS)
[5]. In this context, we showed that the newly developed
transferrin (Tf)-targeted self-assembling nanoparticles
(NPs) incorporating zoledronic acid (ZOL) allowed the
successfully use of ZOL in the treatment of GBM, potenti-
ating its in vitro and in vivo antitumor activity on GBM
through the acquisition of ability to cross the BBB [6].
Despite the aggressive first-line therapy and the recent
results with surgery, radiation therapy and adjuvant
chemotherapy, tumors invariably recur and median sur-
vival is 15 months [7]. Further progress towards a cure for
malignant gliomas will require a greater understanding of
the underlying mechanisms driving the growth and resist-
ance to therapy of these tumors.
In this framework, it is well established that many can-
cers derive from sites of chronic inflammation; the tumor
environment, which is orchestrated by the interplay be-
tween inflammatory cells, tumor cells, and other tumor-
associated host cells, is an essential member in the tumori-
genic progression. Cancer and inflammation are intimately
linked due to specific oxidative processes in the tumor
microenvironment.
In this context, the pro-inflammatory microenviroment
in various human brain tumors is characterized by high ex-
pression of 5-Lipoxygenases (5-LOX) [8], a versatile class of
oxidative enzymes involved in arachidonic acid metabolism,
that promote the proliferation of glioma cells [9–12]. In
addition, is well recognized that the inhibitors of 5-LOX
can activate Caspase-3 inducing glioma cell apoptosis, sug-
gesting that 5-LOX can participate in the survival of glioma
cells [13]. In this context NDGA, a natural 5-LOX inhibitor,
and its methylated derivative, terameprocol, exhibited anti-
cancer activity; moreover, terameprocol is a global tran-
scription inhibitor that affects cell division, apoptosis, drug
resistance, hypoxia responsive genes, and radiation resist-
ance in hypoxia. Previous research indicated terameprocol
as a drug that could be safely combined with radiation in
newly diagnosed high-grade glioma [14].
Starting from these considerations, as cancer is a
multifactor disease, there is great interest in the develop-
ment of new compounds able to target multiple intracel-
lular components.
Our group have been interested for a long time in the
synthesis and the biological evaluation of anti-cancer
and anti-inflammatory agents including quinone-based
compounds [15–26]. Within the context of our investi-
gations towards the synthesis of quinone derivatives with
prospects for therapeutic use, we recently studied the
natural compound embelin, a potent dual inhibitor [18]
of 5-lipoxigenase (5-LOX) and microsomal prostaglan-
din E2 synthase (mPGES)-1 able to suppress prolifera-
tion of human glioma cells and to induce apoptosis by
inhibiting XIAP and NF-κB signaling pathway [27–29].
Moreover, we have previously discovered (RF-Id), an
embelin constrained analogue, with improved efficiency
against 5-LOX in human neutrophils and anti-
inflammatory activity in vivo [15, 19], and the aim of the
present study was to determine the precise cellular mecha-
nisms of the new 5-LOX inhibitor RF-Id and verify its
intrinsic inhibition of XIAP function.
Methods
Materials
All reagents were analytical grade and purchased from
Sigma Aldrich (Milano, Italy). RPMI, DMEM were pur-
chased from Life Technologies (Carlsbad, CA) supple-
mented with 10 % FBS (fetal bovine serum), 1 % penicillin,
streptomycin and L-glutamine from Lonza Group Ltd
(Svizzera). The rabbit antibodies raised against α − tubulin,
caspase-3, detecting endogenous levels of full length
caspase-3 (35 kDa) and the large fragment of caspase-3
resulting from cleavage (17 kDa); caspase-8, detecting en-
dogenous level of total caspase-8 (57 kDa), including the
p10 subnit of the activated protein; caspase-9, detecting en-
dogenous levels of full length caspase-9 (47 kDa), a large
fragment (35 kDa or 17 kDa) and a small fragment
(10 kDa) of caspase-9 resulting from cleavage; p21, p27,
XIAP, C-IAP-2, pIKKα/β, IKKα/β, pIKBα, IKBα and p65
subunit of NFκB were purchased by Cell Signaling Tech-
nology. The rabbit antibody raised against caspase -7 de-
tecting endogenous levels of full length caspase-7 (34 kDa)
was purchased by Santa Cruz Biotechnology.
Chemistry
The compound RF-Id was synthesized and characterized
as reported previously [18]. RF-1d-met was prepared
starting from 1,2,4,5-tetramethoxybenzene and
decahydronaphthalene-2-carbaldehyde. Coupling the
above aldehyde with the lithium anion of 1,2,4,5-tetra-
methoxybenzene (2.5 equiv of BuLi, THF) afforded
compound RF-1d-met as a mixture of diastereomers in
65 % yield.
Cell culture
Human GBM cell lines U87MG and LN229 were pro-
vided by Dr. Carlo Leonetti (Regina Elena Cancer Insti-
tute, Rome, Italy). U87MG and LN229 cells were grown
in RPMI and DMEM, respectively, supplemented with
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10 % heat-inactivated fetal bovine serum, 20 mM
HEPES, 100 U/mL penicillin, 100 mg/mL streptomycin,
1 % L-glutamine and 1 % sodium pyruvate. Cells were
cultured at 37 °C in a 5 % CO2 −95 % air environment
in a humidified incubator.
Cell proliferation assay
Cells were seeded in serum-containing media in 96-well
plates at the density of 2 × 103 cells/well. After 24 h incu-
bation at 37 °C, cells were treated with increasing concen-
trations of RF-Id, embelin and reference compounds
(0,8–100 μM) for 24 h, 48 h and 72 h. Cell viability was
assessed by adding MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] solution in phosphate-
buffered saline (PBS) to a final concentration of 5 mg/mL.
The plates were then incubated at 37 °C for an additional
4 h and the MTT-formazan crystals were solubilized in
1 N isopropanol/hydrochloric acid 10 % solution at 37 °C
on a shaking table for 20 min. The absorbance values of
the solution in each well were measured at 570 nm using
a Bio-Rad 550 microplate reader (Bio-Rad Laboratories,
Milan, Italy). Percentage of cell viability was calculated as
the following formula (absorbance of the treated wells -
absorbance of the blank control wells)/(absorbance of the
negative control wells - absorbance of the blank control
wells). All MTT experiments were performed in
quadruplicate.
Flow cytometric analysis of cell cycle
U87MG cells were seeded in 6-well plates in a number of
2 × 105 cells per well and were treated 24 h later with the
concentration inhibiting 50 % of cell growth (IC:50) of
RF- Id. After 72 h of treatment, cells were washed in PBS
and directly stained in a PI solution (50 μg PI in 0.1 % so-
dium citrate, 0.1 % NP40, pH 7.4) for 30 min at 4 °C in
the dark. Flow cytometry analysis was performed using a
BD Accuri™ C6 (Becton Dickinson). To evaluate cell cycle,
PI fluorescence was collected as FL3 (linear scale) by the
ModFIT software (Becton Dickinson). For the evaluation
of intracellular DNA content, at least 20,000 events for
each point were analyzed in at least three different experi-
ments giving a SD less than 5 %.
Flow cytometric analysis of apoptosis
Apoptotic cell death was analysed by Annexin-V–FITC
staining and by propidium iodide (PI) detection systems
(eBioscences, Vienna, Austria). Briefly, U87MG cells
were seeded in 6-well plates in a number of 2 × 105 cells
per well and were treated 24 h later with Rf-Id IC:50.
After 72 h of treatment cells were trypsinezed, washed
twice with PBS 1X and pellets were resuspended in
200 μL Binding Buffer 1X. Then, 5 μL Annexin V-FITC
were added to 195 μL cell suspension, mixed and incu-
bated for 10 min at room temperature. Cells were
washed with 200 μL Binding Buffer 1×, resuspended in
190 μL Binding buffer 1× and 10 μL Propidium Iodide
(20 μg/mL) was added. The detection of viable cells,
early apoptosis cells, late apoptosis cells and necrotic
cells were performed by BD Accuri™ C6 (Becton Dickin-
son). For each sample, 2 × 104 events were acquired.
Analysis was carried out by triplicate determination on
at least three separate experiments.
Western blot analysis
U87MG cell lines were treated with RF-Id (IC:50) for
24 h, 48 h and 72 h or Bortezomib (500nM) for 24 h or a
combination of Bortezomib and RF-Id for 24 h and 72 h,
respectively at 37 °C. For cell extract preparation, cells
were washed twice with ice-cold PBS, trypsinized and cen-
trifuged for 30 min at 4 °C in 1 ml of lysis buffer (1 % Tri-
ton, 0.5 % sodium deoxycholate, 0.1 NaCl, 1 mM EDTA,
pH 7.5, 10 mM Na2HPO4, pH 7.4, 10 mM PMSF, 25 mM
benzamidin, 1 mM leupeptin, 0.025 units/ml aprotinin).
Equal amounts of cell proteins were separated by SDS-
PAGE in a sample buffer 1× (Sample Buffer 5X: Tris
10 mg/ml, SDS 30 mg/ml, b-mercaptoethanol 0.15 ml,
glycerol 0.3 ml, bromophenol blue), electrotransferred to
nitrocellulose membrane. Membrane were washed in
TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0,05 % Tween
20), and blocked with TBST supplemented with 5 % non-
fat dry milk. Then, membranes were incubate with pri-
mary antibodies in TBST and 5 % nonfat dry milk,
washed, and incubated with horseradish peroxidase-
conjugated secondary antibodies. All primary Abs were
used at a diluition of 1:1000, instead all secondary Abs
were used at a diluition of 1:2000. Blots were then devel-
oped using enhanced chemiluminescence detection re-
agents ECL (Thermo Fisher Scientific, Rockford, IL) and
exposed to x-ray film. All films were scanned by using
Quantity One software (BioRad Chemi Doc).
Flow cytometric analysis of mitochondrial potential
(Mitotracker Red)
Changes in mitochondrial membrane potential due to
ROS generation was analyzed by flow cytometry by using
Mitotracker Red CMXRos (INVITROGEN Carlsbad, Cali-
fornia, Stati Uniti). Briefly, U87MG and LN229 cells were
plated in 6-multiwell plates at the density of 2 × 105 cells/
well. After treatment, cells were detached, centrifuged at
1200 g for 5 min and resuspended in PBS. Mitotracker
Red probe was added at a final concentration of 100 nM.
The latter does not emit fluorescence if it is not internal-
ized in living cells. Mitotracker Red is oxidised in presence
of ROS and emits a red fluorescence (FL2 channel) dir-
ectly proportional to the potential of mitochondrial mem-
brane. After the incubation with probe for 20 min at room
temperature in the dark, cells were centrifuged, resus-
pended and analysed by BD Accuri™ C6. For each sample,
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20,000 events were acquired. Analysis was carried out by
triplicate determination on at least three separate
experiments.
Flow cytometric analysis of autophagy
Autofagy was analyzed by flow cytometry by using mono-
dansylcadaverine (MDC)(Sigma-Aldrich, Saint Louis, Mis-
souri, Stati Uniti) staining. MDC is an auto-florescent
agent used as a selective marker for autophagic vacuoles
(AVOs) and especially autolysosomes. U87MG cells were
plated in 6-multiwell plates at the density of 2 ×105 cells/
well. After 72 h of treatment cells were incubated with
50 μM of MDC in PBS 1x at 37 °C for 15 min. After the
incubation the cells were washed twice in PBS 1×, trypsi-
nized and resuspended in 500 μl of PBS 1×. Analysis was
performed by flow cytometric (BD Accuri™ C6). The fluor-
escent emissions were collected through FL1 channel. For
the quantitative evaluation of MDC, BD Accuri™ C6 soft-
ware (Becton Dickinson) was used to calculate MFIs. The
MFIs were calculated by the formula (MFI treated/MFI
control), where MFI treated is the fluorescence intensity
of cells treated with the various compounds and MFI con-
trol is the fluorescence intensity of untreated and un-
stained cells. For each sample, 20,000 events were
acquired. Analysis was carried out by triplicate determin-
ation on at least three separate experiments.
RNA extraction and Taqman Human Apoptosis Array-
Real-Time-PCR
Total RNA was prepared from U87MG cells according to
mirVana PARIS (Ambion) protocol. In details, cells were
centrifuged at 1,500 rpm for 5 min; the pellets obtained
were placed on ice and then resuspended in 300 μl of Dis-
ruption Buffer. Successively, an equal volume of Denatur-
ing Buffer (previously set at 37 °C) was added to the
pellets and they were incubated in ice for 5–10 min. Then,
Phenol-chloroform was added in the tube in a volume
equal to the total volume and centrifugated at 10,000 rcf
for 5 min. After centrifugation, the aqueous phase was
collected and a volume of absolute ethanol equal to 1.25
times that of the collected volume was added. Then
700 μL at a time were collected, applied in Filter Cartridge
and centrifuged at 10,000 rcf for 5 min. 700 μL of Wash
Solution 1 were added on each Filter Cartridge, followed
by centrifugation at 10,000 rcf for 40 s, later two washings
with 500 μl of Wash Solution 2 were performed. Finally,
50 μl of Eluition Buffer (preheated at 95 °C) were added to
the Filter Cartridge, previously placed on new tubes. Then,
the samples were quantized to Nanodrop (Technologies
Inc., Wilmington, DE). The cDNA was obtained by using
QuantiTect Reverse Transcription Kit, (Quiagen) accord-
ing to the manufacturer’s instructions. PCR products for
all the genes tested were assessed in triplicate wells using
TaqMan pre-developed assay reagents. The arithmetic
standard normalization procedures recommended by the
Data Assist software for microarray data were followed. In
brief, data transformation was corrected for the signal
from the three endogenous controls (18S, ACTB,
GAPDH). Per card (mean) normalization accounted for
the variability of each card by dividing all of the measure-
ments on each card by the value of the 50th percentile.
Per gene normalization accounted for the variability be-
tween probe sets for the three reporter genes. The thresh-
old cycle, Ct, was automatically assigned by the SDS2.2
software package (Applied Biosystems). Relative quantities
(RQ) were determined using the equation RQ= 2 −ΔΔCt.
All data were generated in triplicate (different TLDA
plates) and expressed as the mean ± SD. Differentially
expressed genes were selected from the normalized data
using a procedure known as significance analysis of micro-
arrays, as installed in the SDS2.3 software package (Ap-
plied Biosystems). Genes were considered to be significant
when their average fold change (FC) was ≤ −1.5 or ≥1.5,
and statistically significant when the corresponding p
value was ≤0.05. Two software programs were used to
analyze the data, namely SDS RQ Manager 1.2 and
DataAssist v.2.2 software (Applied Biosystems).
Taqman human apoptosis array contains 93 human
genes in addition to 3 endogenous controls (18S, ACTB,
GAPDH). Real-time quantitative PCR was performed on
a ViiA7™ Real time PCR system (Applied Biosystems,
Darmstadt, Germany). Relative expression of the tran-
scripts was measured by using ViiA7™Real-Time PCR
software (Applied Biosystems, Darmstadt, Germany).
Treated samples were normalized to the corresponding
medium-only control.
Immunoprecipitation
Total protein extracts were subjected to immunoprecipita-
tion with 2 μg of anti-XIAP or anti-cIAP2 for 24 h at 4 °C.
Immune complexes were collected with 50 μl of protein
A-agarose for 16 h at 4 °C. The protein A-agarose/immune
complex was washed twice with cold PBS, resuspended in
20 μl of SDS-loading buffer, heated to 95 °C for 5 min and
used for Western blotting analysis using anti-XIAP or anti-
CIAP2.
Statistical analysis
All data are expressed as mean + SD. Statistical analysis was
performed by analysis of variance (ANOVA) with
Neumann-Keul’s multiple comparison test or Kolmogorov-
Smirnov test where appropriate.
Results
Effects of RF-Id on the proliferation of GBM cells
In order to investigate the antitumor activity of the new
benzoquinone derivatives, we evaluated the effects of RF-
Id, RF-Idmet and embelin on cell growth of two human
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GBM cell lines (U87MG and LN229) after 24 h, 48 h and
72 h of treatment. Cell growth inhibition was evaluated by
cell viability assay as described in “Materials and methods”
and resulted time- and dose-dependent for all com-
pounds. In details, after 72 h RF-Id and RF-Idmet induced
50 % (IC:50) of growth inhibition at a concentration of
23.6 and 47.5 μM in the U87MG and 77 and 100 μM in
LN229, respectively while IC:50 of embelin was 30 μM in
U87MG and 33 μM in LN229 (Fig. 1).
On the other hand, NDGA, a natural 5-LOX inhibitor
and its methylated derivative terameprocol inhibited 50 %
of cell growth at a concentration of 87 and >50 μM in
U87MG and >50 μM in LN229, respectively, as reported
in Table 1. In conclusion, RF-Id was more potent than its
methylated derivative and embelin in inducing growth in-
hibition on U87MG cells.
Effects of RF-Id on cell cycle modulation
In order to study the molecular mechanisms of the anti-
proliferative activity of RF-Id, we performed cell cycle
analysis by flow cytometry. On the basis of the IC:50
values, U87MG cells resulted more sensitive to the treat-
ment with RF-Id and were selected for subsequent ex-
periments. Cells were treated for 72 h with RF-Id and,
subsequently, were stained with propidium iodide for
1 h and analyzed by flow cytometry. For each sample,
the percentage of cells in each phase of the cell cycle
(G0/G1-S-G2M) was calculated.
Cell cycle analysis showed that treatment with RF-Id in-
duced an increase of S and G2/M cells and a decrease of
G0/G1 (Fig. 2). In details, as reported in the histogram,
the percentage of cells in S phase and G2/M was equal to
35 and 20 %, respectively, in the control while it increased
Fig. 1 Effects of RF-Id (a), RF-Idmet(b) and embelin(c) on cell growth inhibition. Human GBM cells U87MG and LN229 were seeded in serum-containing
media in 96-well plates at the density of 2 × 103 cells/well. After 24 h incubation at 37 °C, cells were treated with increasing concentrations of RF-Id (a),
RF-Idmet (b) and embelin (c) (0,8–100 μM) for 72 h. Cell viability was assessed by MTT assay as described in Material and methods. ** p≤ 0.01
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(about 45 and 30 %, respectively) with the treatment; on
the other hand, the percentage of cells in G0/G1 de-
creased from 45 to 35 % after treatment with RF-Id.
Effects of RF-Id on apoptosis
Subsequently, we evaluated the effects of RF-Id on
apoptosis by flow cytometry. After 72 h of treatment,
U87MG cells were stained with Annexin V-FITC and
propidium iodide and analyzed by flow cytometry. As
shown in Fig. 3, RF-Id induced about 30 % of apoptosis
compared to control cells (1,6 %); in details, 24 % of the
cells were in late apoptosis and 12 % in early apoptosis.
No significant effects were recorded on necrosis. In con-
clusion, RF-Id showed a significant pro-apoptotic effect.
In order to confirm the apoptotic effect induced by
RF-Id on U87MG cells, we examined its effects on cas-
pase cascade by Western blotting technique (Fig. 4). In
details, the cells treated for 24, 48, 72 h as described in
Materials and Methods, were lysed and proteic lysates
were analyzed by Western blotting. After 24 and 48 h of
treatment no significant effects on the expression of cas-
pases was observed while after 72 h RF-Id induced an
increase of procaspases 3, 7, 8 and 9 and a significant in-
crease of the cleaved fragments, indicative of caspase ac-
tivation (Fig. 4). In addition, treatment with RF-Id did
not alter the levels of p21 and p27 after 24 and 48 h
while they significantly increased after 72 h (Fig. 4). This
effect on p21 and p27 expression was likely due to a de-
crease of protein ubiquitination and consequently to p21
Table 1 IC:50 values of the different compounds in U87MG and LN229 cells after 72 h of treatment
Name Structure Cell line IC50 [µM]
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Fig. 3 Effects of RF-Id on apoptosis. U87 MG cells were not treated or treated with RF-Id IC:50 for 72 h. Apoptosis was evaluated by FACS analysis, after
double cell labeling with propidium iodide (PI) and Annexin V-FITC. The lower left quadrants of each panel show the viable cells, which exclude PI and are
negative for AnnexinV-FITC binding. The upper left quadrants contain the non-viable, necrotic cells, negative for Annexin V-FITC binding and positive for PI
uptake. The lower right quadrants represent cells in early apoptosis that are Annexin V-FITC positive and PI negative. The upper right quadrants represent
the cells in late apoptosis, positive for both Annexin V-FITC binding and for PI uptake. The experiments were performed at least three times and the results
were always similar
Fig. 2 Effects of RF-Id on cell cycle. U87-MG cells were treated for 72 h with IC:50 of RF-Id and subsequently were stained with propidium iodide for
1 h and analyzed by flow cytometry. For each sample, the percentage of cells in each phase of the cell cycle (G0 / G1-S-G2M) was calculated. The ex-
periments were repeated three times giving always similar results. Bars, SDs. ** p≤ 0.01
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and p27 accumulation. In fact, we showed (Additional
file 1: Figure S1) that after 72 h, Rf-Id treatment de-
creased ubiquitinated form of p21. In conclusion, RF-Id
was able to induce apoptosis by a caspase-dependent
mechanism.
Effects of RF-Id on mitochondrial membrane potential
and autophagy
We evaluated the effects of RF-Id on mitochondrial
membrane potential by flow cytometry. Cells were
treated for 72 h at concentrations equal to IC:50 and
stained with Mitotracker dye which localized in mito-
chondria and changed in according to mitochondrial
membrane potential variations due to oxidative stress.
RF-Id did not induce significant effects (110 % MFI) on
the membrane potential of U87MG cells compared to
control (100 % MFI) (Fig. 5a). In addition, we evaluated
the effects of RF-Id on autophagy.
In details, cells were treated for 72 h and subsequently
were stained with MDC, specific marker for autophago-
somes and analyzed by flow cytometry. Analysis of the
data showed that treatment with RF-Id induced a slight
increase of autophagy in U87MG (120 % MFI) compared
to control (100 % MFI) (Fig. 5b).
Identification of RF-Id regulated genes in apoptosis
On the basis of the data demonstrating that RF-Id in-
duced caspase-dependent cell death in U87MG cells, we
assessed more globally the mechanisms involved in RF-
Id-induced apoptosis using microarray analysis. There-
fore, RNA was prepared from either untreated U87MG
cells or cells exposed to RF-Id for 72 h. Three biological
replicates were performed per group. Data were normal-
ized using the glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), ACTB and 18S genes as internal control.
After 72 h of treatment, differential gene expression
Fig. 4 Effects of RF-Id on signal transduction pathways. U87MG cells were treated for 72 h with IC:50 of RF-Id. Cell lysates were incubated with anti-
human caspases 8, 3, 7, 9, p21 and p27 antibodies and analysed by Western Blotting; the housekeeping protein α-tubulin was used as loading control. The
experiments were repeated three times giving always similar results. Quantitation of the bands for each proteins are reported in Additional file 1: Figure S3
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analysis revealed 10 significantly modulated transcripts
(8 decreased and 2 increased) in RF-Id-treated cells
compared to controls. In particular, BIRC2, BIRC4,
BIRC5 and BIRC6, NFκB1, NFκBIA, CASP6 and BNIP3
were downregulated. At this time, CASP8 and NFκBIZ
were the only upregulated genes detected in this analysis
(Fig. 6). Other genes did not show highly significant
changes as reported in Additional file 1: Table S1. Intri-
guingly, most of the upregulated genes were associated
to extrinsic pathway (CASP8) while downregulated genes
belonged to IAP family and NFκB pathway.
RF-Id inhibits XIAP-cIAP2 interaction
Since RF-Id dowregulated genes belonged to IAP family
and NFκB pathway and embelin inhibits the X-linked in-
hibitor of apoptosis protein (XIAP) by binding to its
Baculovirus Inhibitor of apoptosis protein Repeat (BIR) do-
main, we investigated the action mechanism of the com-
pound. Recent evidence showed that XIAP stabilizes
c-IAP2 at the protein level by inhibiting its auto-
ubiquitination and the increased expression of c-IAP2 en-
hances the phosphorylation of IκBα that favours its subse-
quent proteasomal degradation leading to activation of the
canonical NFκB pathway. In order to investigate if RF-Id
disrupts XIAP-cIAP2 complex by inhibiting NFκB pathway,
we evaluated the effects of RF-Id on either XIAP, cIAP2
and XIAP –cIAP2 complex expression and on IKKα/β,
IKBα and NFκB activation and expression. After 72 h RF-
Id induced an increase of c-IAP2, a decrease of XIAP and
significantly reduced the complex (Fig. 7a). Probably, RF-Id
reduced XIAP by increasing its degradation, since bortezo-
mib blocked RF-Id mediated-XIAP degradation and
Fig. 5 Effects of RF-Id on mitochondrial membrane potential and autophagy. Flow cytometric analysis of mitochondrial membrane potential by using
Mitotracker red, dye which localized in mitochondria and changed in according to mitochondrial membrane potential variations due to oxidative stress.
U87 MG cells were treated with RF-Id for 72 h. (Right panels) The %MFIs of control were calculated, as described in ‘Materials and Methods’ and repre-
sented as columns. The experiments were performed at least three times and the results were always similar. Bars, SDs.** p≤ 0.01 (a) Flow cytometric ana-
lysis of autophagosome formation (MDC incorporation) in U87 MG cells treated with RF-Id for 72 h. (Right panels) The %MFIs of control were calculated, as
described in ‘Materials and Methods’ and represented as columns. The experiments were performed at least three times and the results were always similar.
Bars, SDs. ** p≤ 0.01
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increased its expression. Moreover, RF-Id reduced IKKα/β
and IkBα phosphorilation by increasing IKBα expression
thus inhibiting NFκB (Fig. 7b). On the other hand, bortezo-
mib antagonized the effects of RF-Id by increasing XIAP–
cIAP-2 complex and leading to IKKα/β-mediated IkBα
phosphorylation and degradation (Fig. 7b). Moreover, Rf-Id
mediated both apoptosis and caspase activation through
degradation of XIAP, that acts as apoptosis inhibitor by
binding caspases 9, 3 and 7. Bortezomib antagonized Rf-Id-
mediated caspase activation as it blocked XIAP degradation
making XIAP able to inhibit both caspases activity and
apoptosis identified as “DNA ladder” by agarose gel electro-
phoresis (Additional file 1: Figure S2).
In conclusion, RF-Id inhibited cIAP2-XIAP complex
formation and IkBα degradation by leading to NFκB in-
hibition and caspase activation.
Discussion
Several benzoquinones have been found effective in treat-
ing some forms of cancer [17]; in details, it has been
shown that these compounds act on cells by regulating
numerous mechanisms, such as apoptosis, cell cycle [30],
interacting with human-telomeric G-quadruplex DNA
[31] or producing reactive oxygen species (ROS) [32]. Our
group has been interested for a long time in synthesis and
biological evaluation of anti-inflammatory and anti-cancer
agents including quinone-based compounds [20–23].
Within the context of our investigations on quinone deriv-
atives and on their possible therapeutic use, we recently
studied the natural compound embelin and the synthetic
derivative RF-Id [15, 19]. Previous research has demon-
strated that embelin, a small inhibitor binding the Baculo-
virus Inhibitor of apoptosis protein Repeat (BIR) domain
of the X-linked inhibitor of apoptosis protein (XIAP),
suppressed proliferation of human glioma cells and in-
duced apoptosis by inhibiting NF-κB signaling pathway.
Our previous work revealed embelin as potent dual inhibi-
tor of 5-LOX and microsomal prostaglandin E2 synthase
(mPGES)-1 with IC50 values of 60 and 200 nM in cell-free
assays, respectively. Moreover RF-Id, demonstrated an
improved efficiency against 5-LOX in human neutrophils
(IC50 = 580 nM) and in vivo anti-inflammatory activity.
The high potency on 5-LOX and the promising in vivo
efficiency of synthesized compound prompted us to in-
vestigate the RF-Id antiproliferative effects in GBM
tumor cell lines.
We showed that RF-Id had two major time-dependent in
vitro consequences on U87-MG cells. This compound
modulated cell cycle arrest and drove cells to programmed
cell death by inhibiting cIAP2-XIAP complex formation
and IkBα degradation and leading to NFκB pathway
inactivation.
First, we found that RF-Id was more potent than its
methylated derivative and embelin in inducing growth
inhibition on GBM cells, in particular on U87MG cells.
In order to study the molecular mechanisms of the anti-
proliferative activity of RF-Id, we performed cell cycle and
apoptosis analysis by flow cytometry. In details, after 72 h
RF-Id induced about 30 % apoptosis and cell death was
mediated by caspases and occurred through a ROS-
independent mechanism. In fact, the compound induced a
significant cleavage of the initiator caspases 8, 9, and of ef-
fector caspases 3 and 7 but did not induce significant alter-
ations of the mitochondrial membrane potential associated
to increased ROS production in mitochondria. Moreover,
the compound induced an increase in the percentage of
cells in G2 and S phase that occurred in parallel to an in-
crease of the expression of p21 and p27. The increase of
Fig. 6 RF-Id -regulated genes in U87MG cells. RNA was prepared from unexposed U87MG cells and exposed to RF-Id for 72 h. Data were
normalized using GAPDH, 18S and ACTB genes as internal control. Three biological replicates were performed per group. Relative expression of
the transcripts was measured by using ViiA7™Real-Time PCR software. Bars, SDs.** p≤ 0.01
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p21 and p27 could be due to a decrease of protein ubiquiti-
nation and hence, a reduced degradation rather than to an
increase of gene transcription. In fact, XIAP or c-IAP2 may
act as E3-ubiquitin ligases promoting the degradation of
CDK inhibitors, p21 and p27 [33]. We recorded a late in-
crease of p21 and p27 expression after treatment with Rf-Id
that could be due to a decrease of protein ubiquitination
and consequently to p21 and p27 accumulation. This effect
on p21 and p27 expression can be likely ascribed to RF-Id
that induces XIAP degradation and c-IAP2 inhibition,
blocks their ubiquitin ligases activity and reduces p21 and
p27 degradation by proteosome. As shown in Additional
file 1, we found a decrease of ubiquitinated form of p21
after 72 h from the beginning of Rf-Id treatment.
In addition, RF-Id induced only a slight 20%increase
of autophagy that may be due to a blockage of the au-
tophagic flow that causes an accumulation of MDC,
marker of autophagosomes. The action mechanism of
RF-Id was confirmed by performing apoptosis array.
Data analysis, in fact, showed a significant upregulation
of CASP8 and a downregulation of IAP family proteins
(BIRC2, 4,5,6 and 7) and NFκB in cells treated with RF-
Id for 72 h. Probably, RF-Id acts by inhibiting IAP
family genes (XIAP, c-IAP1, c-IAP2) and NFκB pathway
and inducing apoptosis through both intrinsic and ex-
trinsic pathways thus, resulting in the amplification of
the apoptotic signal.
Recent evidence showed that XIAP stabilizes c-IAP2 at
the protein level by inhibiting its auto-ubiquitination and
the increased expression of c-IAP2 enhances the phosphor-
ylation of IκBα that favours its subsequent proteasomal
degradation leading to activation of the canonical NFκB
pathway [34, 35]. In fact, we hypothesized that RF-1d by
inhibiting XIAP could decrease c-IAP2, but we found that
c-IAP2 was indeed increased. Based on these results, we
suggest that RF-Id could disrupt XIAP-cIAP2 binding by
inducing XIAP ubiquitination and proteosome-mediated
degradation as bortezomib blocked RF-Id-mediated XIAP
degradation and increased its expression. On this light, RF-
Id could bind and stabilize c-IAP2 at the protein level by
displacing XIAP but inhibits its activity as caspase inhibitor
by blocking BIR3 domain of c-IAP2, as a consequence we
found that RF-Id activated caspases 3, 7, 8 and 9. Binding
of the XIAP RING domain to c-IAP2 is a pre-requisite for
stabilization of c-IAP2, even though the RING activity may
be defective, suggesting that occupation of BIR domains 2
Fig. 7 RF-Id inhibits XIAP-cIAP2 interaction and NFκB activation. Total protein extracts were subjected to immunoprecipitation with 2 μg of anti-XIAP or
anti-cIAP2 for 24 h at 4 °C. Immune complexes were collected with 50 μl of protein A-agarose for 16 h at 4 °C. The protein A-agarose/immune complex
was washed twice with cold PBS, resuspended in 20 μl of SDS-loading buffer, heated to 95 °C for 5 min and used for Western blotting analysis using anti-
XIAP or anti-CIAP2 . Representation of the c-IAP2 and XIAP complexes was expressed as the mean of the ratio between the relative intensities of the bands
associated with the c-IAP2/XIAP complexes versus the bands associated with total C-IAP2 and XIAP, respectively. The intensities of the
bands were expressed as arbitrary units when compared to that of the untreated cells. Error bars showed standard deviation from the
mean in at least three independent experiments. Bars, SDs.** p ≤ 0.01 (a). U87MG cells were treated for 72 h with IC:50 of RF-Id or
500nM Bortezomib for 24 h or a combination of RF-Id and Bortezomib. Cell lysates were incubated with anti-human c-IAP2, pIKKα/β,
IKKα/β, pIKBα, IKBα and NFκB antibodies and analysed by Western Blotting; the housekeeping protein α-tubulin was used as loading
control. The experiments were repeated three times giving always similar results. Quantitation of the bands for each proteins are reported
in Additional file 1: Figure S4 (b)
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and 3 on c-IAP2 by XIAP through its RING finger guaran-
tees the ensuing increase in c-IAP2 stability. Protein inter-
actions occur through binding of BIR2 and BIR3 domains
of c-IAP2 with the RING finger of XIAP. RF-Id probably
binds BIR3 domain of c-IAP2 and stabilizes it by blocking
its degradation but inhibits its caspase inhibitor activity so
that the BIR-bound caspases are released and reactivated;
in the same time, Rf-Id displaces XIAP that undergoes to
auto-ubiquitination and is degraded via proteosome. More-
over, Rf-Id acts inhibiting c-IAP1 while c-IAP2 undergoes
to a posttranscriptional regulation; it increases because its
degradation is reduced. In fact, it is reported that cells from
c-IAP1(-/-) mice express markedly elevated levels of c-IAP2
protein in the absence of increased c-IAP2 mRNA. Transi-
ent transfection studies with wild-type and E3-defective c-
IAP1 revealed that c-IAP2 is a direct target for c-IAP1-
mediated ubiquitination and subsequent degradation [36].
Blockade of cIAP2-XIAP complex formation increased
IkBα expression leading to NFκB inhibition and apop-
tosis induction by reducing survivin and FLIP, a caspase
8 inhibitor as confirmed by microarray analysis (Fig. 8).
On the other hand, bortezomib antagonized the effects
of RF-Id by increasing XIAP–cIAP2 complex leading to
IKKα/β-mediated IKBα phosphorylation and NFκB activa-
tion as it blocked RF-Id-mediated XIAP degradation [37].
As reported in the literature [38], Bortezomib downregu-
lated cIAP2 expression, probably by a NFκB-independent
mechanism. Moreover, Rf-Id mediated both apoptosis and
caspase activation through degradation of XIAP, that acts
as apoptosis inhibitor by binding caspases 9, 3 and 7. Bor-
tezomib antagonized Rf-Id-mediated caspase activation as
it blocked XIAP degradation making XIAP able to inhibit
caspase-mediated apoptosis.
Conclusions
RF-Id induced apoptosis associated with modulation of
cell cycle on U87MG by inducing XIAP degradation and
inhibiting NFκB pathway. In conclusion, RF-Id could rep-
resent a new therapeutic strategy in GBM, due to its
highly lipophilic structure, able to target multiple intracel-
lular components.
Additional file
Additional file 1: Figure S1. Rf-Id induced p21 accumulation through a
decrease of its ubiquitination. U87MG cells were treated for 72h with
IC:50 of RF-Id. Total protein extracts were subjected to immunoprecipita-
tion with 2 μg of anti-p21 for 24 h at 4 °C. Immune complexes were col-
lected with 50 μl of protein A-agarose for 16 h at 4 °C. The protein A-
agarose/immune complex was washed twice with cold PBS, resuspended
in 20 μl of SDS-loading buffer, heated to 95 °C for 5 min and used for
Western blotting analysis using anti-ubiquitin antibody.(Ub-p21: ubiquiti-
nated p21). Figure S2. Rf-Id induced apoptosis in glioblastoma cells.
U87MG were untreated (Lane 1) or treated with 72h with IC:50 of RF-Id
(Lane2) or 500 nM Bortezomib for 24h (Lane 3) or a combination of RF-Id
and Bortezomib (Lane 4). Chromosomal DNA was prepared using the
Quick Apoptotic DNA ladder Detection kit according to the kit instruc-
tions. 10 μL of each sample was electrophoresed on a 1.5% agarose/EtBr
gel (A). U87MG cells were treated for 72h with IC:50 of RF-Id or 500 nM
Fig. 8 RF-Id inhibits cIAP2 and XIAP activity and NFκB pathway. RF-Id disrupts XIAP-cIAP2 binding by inducing XIAP ubiquitination and proteosome-
mediated degradation. Moreover, RF-Id stabilizes c-IAP2 at the protein level but inhibits its activity as caspases inhibitor by blocking BIR3 domain of cIAP2,
thus activating caspases 3,7, 8 and 9. Moreover, blockade of cIAP2-XIAP complex formation increases IkBα expression leading to NFκB inactivation and
apoptosis induction
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Bortezomib for 24h or a combination of RF-Id and Bortezomib. Cell ly-
sates were incubated with anti-human XIAP, caspase 3 and 7 antibodies
and analysed by Western Blotting; the housekeeping protein α-tubulin
was used as loading control. The experiments were repeated three times
giving always similar results (B). Figure S3 Effects of RF-Id on signal trans-
duction pathway. The intensities of the bands were expressed as arbitrary
units when compared to that of the untreated cells and normalized for
α-tubulin. Error bars showed standard deviation from the mean in at least
three independent experiments. Bars, SDs .** p≤0.01 Figure S4 RF-Id in-
hibits XIAP-cIAP2 interaction and NFκB activation. The intensities of the
bands were expressed as arbitrary units when compared to that of the
untreated cells and normalized for α-tubulin. Error bars showed standard
deviation from the mean in at least three independent experiments. Bars,
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